Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
PLoS Pathog ; 20(5): e1012211, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38709823

RESUMEN

Cytolytic CD8+ T cells mediate immunopathology in cutaneous leishmaniasis without controlling parasites. Here, we identify factors involved in CD8+ T cell migration to the lesion that could be targeted to ameliorate disease severity. CCR5 was the most highly expressed chemokine receptor in patient lesions, and the high expression of CCL3 and CCL4, CCR5 ligands, was associated with delayed healing of lesions. To test the requirement for CCR5, Leishmania-infected Rag1-/- mice were reconstituted with CCR5-/- CD8+ T cells. We found that these mice developed smaller lesions accompanied by a reduction in CD8+ T cell numbers compared to controls. We confirmed these findings by showing that the inhibition of CCR5 with maraviroc, a selective inhibitor of CCR5, reduced lesion development without affecting the parasite burden. Together, these results reveal that CD8+ T cells migrate to leishmanial lesions in a CCR5-dependent manner and that blocking CCR5 prevents CD8+ T cell-mediated pathology.


Asunto(s)
Linfocitos T CD8-positivos , Movimiento Celular , Leishmaniasis Cutánea , Receptores CCR5 , Animales , Receptores CCR5/metabolismo , Receptores CCR5/inmunología , Linfocitos T CD8-positivos/inmunología , Ratones , Humanos , Leishmaniasis Cutánea/inmunología , Leishmaniasis Cutánea/parasitología , Leishmaniasis Cutánea/patología , Ratones Noqueados , Ratones Endogámicos C57BL , Antagonistas de los Receptores CCR5/farmacología , Maraviroc/farmacología , Femenino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA